SCHEMBL8117441

SCHEMBL8117441

Brc1nc[nH]c1-c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
CYP3A4 P08684 2/20 0.61
MAPT P10636 1/20 0.61
IDO1 P14902 5/20 0.56
DYRK1A Q13627 1/20 0.42
MAPK14 Q16539 4/20 0.39
DYRK1B Q9Y463 1/20 0.39
DPP4 P27487 1/20 0.38
MTOR P42345 1/20 0.38
ADK P55263 1/20 0.38
NISCH Q9Y2I1 1/20 0.38
ALDH1A1 P00352 4/20 0.37
POLB P06746 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
ADORA3 P0DMS8 2/20 0.37
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
MAPK13 O15264 1/20 0.37
GCGR P47871 1/20 0.37
MAPK12 P53778 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18731561 0.86 KDM4E (0.43) KDM4ECYP3A4MAPTIDO1DYRK1A
SCHEMBL224770 0.76 KDM4E (1.00) KDM4ECYP3A4MAPTIDO1DYRK1A
Bromide SCHEMBL31020961 0.74 KDM4E (0.96) KDM4ECYP3A4MAPTIDO1DYRK1A
SCHEMBL1501808 0.74 KDM4E (0.61) KDM4ECYP3A4MAPTIDO1DYRK1A
SCHEMBL9324003 0.74 KDM4E (0.61) KDM4ECYP3A4MAPTIDO1DYRK1A
SCHEMBL11000595 0.74 CYP3A4 (0.61) KDM4ECYP3A4MAPTIDO1DYRK1A
SCHEMBL18731544 0.72 IDO1 (0.51) CYP3A4MAPTIDO1POLB
Bromide SCHEMBL10355410 0.72 CYP3A4 (0.58) KDM4ECYP3A4MAPTIDO1DYRK1A
SCHEMBL8117885 0.70 KDM4E (0.61) KDM4ECYP3A4MAPTIDO1DYRK1A
SCHEMBL7442855 0.69 KDM4E (0.60) KDM4ECYP3A4MAPTIDO1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029158-A EGFR inhibitors 缆图药品公司 2026-05-12 CN disclosed
EP-4584259-A1 CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS Innovo Therapeutics, Inc. (US) 2025-07-16 EP disclosed
WO-2025080784-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2025-04-17 WO disclosed
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. 2024-05-16 US disclosed
WO-2024054832-A1 CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
CN-1109021-C Method of producing N, N'-diazole compounds PPG INDUSTRIES INC (US) 2003-05-21 CN disclosed
EP-1019381-A1 METHOD OF PRODUCING N,N'-DIAZOLE COMPOUNDS PPG INDUSTRIES, INC. (US) 2000-07-19 EP disclosed
CN-1248247-A Preparation method of N, N' -diazole compound PPG INDUSTRIES INC (US) 2000-03-22 CN disclosed
WO-1998031672-A1 METHOD OF PRODUCING N,N'-DIAZOLE COMPOUNDS PPG INDUSTRIES OHIO, INC. (US) 1998-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS CKS1B, CKS2, MARK1 KDM4E 1794/4885CYP3A4 3790/4885MAPT 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.